11 completed, 2 terminated, 1 unknown. 14 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 14 | Completed 11, Terminated 2, Unknown 1 |
| Phase 2 | 1 | Terminated 1 |
Follow Long QT Syndrome: new trials by email Literature Review of Long QT Syndrome trials Research Report on Long QT Syndrome
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of LQT-1213 on QTc-induced Prolongation in Healthy Adult Subjects (Part1) and on Congenital Long QT in Patients Diagnosed With Type 2 or 3 Long QT Syndrome (Part 2). LQT-1213, Placebo, Dofetilide 250 μg Cap - Long QT Syndrome | Phase 1 / Phase 2 | Terminated | Thryv Therapeutics, Inc. | 42 | 2023-03-12 | 2025-07-24 |
| Phase 1 Study of LQT-1213 in Healthy Adults LQT-1213, Placebo - Long QT Syndrome | Phase 1 | Completed | Thryv Therapeutics, Inc. | 50 | 2022-09-14 | 2023-09-26 |
| A Study to Investigate the Effect of Single Dose of AZD6094 (600 mg) on Cardiac Repolarization in Healthy Volunteers AZD6094 200 mg, Placebo, Moxifloxacin - Solid Tumors | Phase 1 | Completed | AstraZeneca | 45 | 2017-09-06 | 2020-02-20 |
| Pharmacokinetics of Eleclazine in Adults With Normal and Impaired Renal Function Eleclazine - Long QT Syndrome | Phase 1 | Completed | Gilead Sciences | 55 | 2015-05-01 | 2015-12-22 |
| Pharmacokinetics of Eleclazine in Adults With Normal and Impaired Hepatic Function Eleclazine - Long QT Syndrome | Phase 1 | Completed | Gilead Sciences | 49 | 2015-03-19 | 2019-07-29 |
| Effect of Oral GS-6615 on Dofetilide-Induced QT Prolongation, Safety, and Tolerability in Healthy Adults GS-6615, Placebo to match GS-6615, Placebo to match dofetilide - Long QT Syndrome | Phase 1 | Completed | Gilead Sciences | 60 | 2015-02-01 | 2015-05-20 |
| Race Difference Moxifloxacin-induced QT Prolongation Between Healthy Chinese and Caucasian Volunteers Moxifloxacin - Cardiac Toxicity | Phase 1 | Unknown | Haiyan Li | 80 | 2014-04-01 | 2014-04-21 |
| A Dose Ranging Escalation Study of Tramadol Hydrochloride in Healthy Volunteers Tramadol HCl, 50 mg, Placebo - Healthy | Phase 1 | Completed | Janssen Scientific Affairs, LLC | 30 | 2013-08-01 | 2014-12-16 |
| Study of the Effect of GS-6615 in Subjects With LQT-3 GS-6615 - Long QT Syndrome | Phase 1 | Completed | Gilead Sciences | 24 | 2013-05-01 | 2014-11-17 |
| Effect of Potassium and Acetazolamide on People With Andersen-Tawil Syndrome Potassium, Acetazolamide - Andersen-Tawil Syndrome | Phase 1 | Terminated | University of Rochester | 3 | 2008-12-01 | 2012-01-20 |
| Genetic Sources of Variability of the Adaptation of the Ventricular Repolarisation Sotalol 80 mg - Healthy Volunteers | Phase 1 | Completed | Assistance Publique - Hôpitaux de Paris | 997 | 2008-02-01 | 2012-07-26 |
| Methadone Pharmacokinetics and Cardiac Effects in Newborns Methadone HCl Inject 10 mg/ml (will require dilution), Methadone - Pain | Phase 1 | Completed | University of Utah | 7 | 2007-10-01 | 2022-06-01 |
| Study Evaluating the Effects of Multiple Oral Doses of ERB-041 on Cardiac Repolarization in Healthy Subjects ERB-041 - Healthy, Long QT Syndrome | Phase 1 | Completed | Wyeth is now a wholly owned subsidiary of Pfizer | 64 | 2006-05-01 | 2007-04-13 |
| Evaluation of Possible Effects on the QT/ QTc Interval of Rupatadine in Healthy Volunteers Rupatadine, moxifloxacin, Continous electrocardiographic register - Human Experimentation (Human Volunteers) | Phase 1 | Completed | J. Uriach and Company | 160 | 2005-02-01 | 2005-12-15 |
Pain (2) · Agnosia (1) · Andersen Syndrome (1) · Cardiotoxicity (1) · Renal Insufficiency (1)
Arrhythmias, Cardiac (14) · Cardiac Conduction System Disease (14) · Cardiovascular Abnormalities (14) · Cardiovascular Diseases (14) · Congenital Abnormalities (14) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (14) · Heart Defects, Congenital (14) · Heart Diseases (14) · Pathologic Processes (14) · Pathological Conditions, Signs and Symptoms (14) · Neurologic Manifestations (2) · Signs and Symptoms (2) · Chemically-Induced Disorders (1) · Drug-Related Side Effects and Adverse Reactions (1) · Female Urogenital Diseases (1)
eleclazine (4) · Moxifloxacin (3) · dofetilide (2) · 1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine (1) · Acetazolamide (1) · Capsules (1) · ERB 041 (1) · Methadone (1) · Potassium (1) · Sotalol (1) · Tramadol (1) · rupatadine (1)
Gilead Sciences (4) · Thryv Therapeutics, Inc. (2) · Assistance Publique - Hôpitaux de Paris (1) · AstraZeneca (1) · Haiyan Li (1) · J. Uriach and Company (1) · Janssen Scientific Affairs, LLC (1) · University of Rochester (1) · University of Utah (1) · Wyeth is now a wholly owned subsidiary of Pfizer (1)
United States (12) · Romania (2) · China (1) · France (1) · Germany (1) · Moldova (1) · New Zealand (1) · Spain (1)
Beny Charbit, MD (1) · Brian McNabb, MD (1) · Elizabeth Layug, MD (1) · Esther G Donado, PhD (1) · Haiyan Li, MD (1) · Jan Matousek, DO (1) · Kimberly B Patel, MD (1) · Manuel Barbanoj, MD (1) · Paul Twydell, DO (1) · Robert Ward, M.D. (1) · Ronald Goldwater, MD (1)
PMID 24666686, PMID 28800628, PMID 33400845, PMID 33733338
2014 (2), U10HD045986 (1), U54NS059065 (1)